The 340B Rebate Trap -By Fransiscus Nanga Roka

The battle between the American Hospital Association (AHA) and the federal effort to impose a Medicare/340B rebate model is not simply a technical issue regarding billing mechanics. It is a face-off as to who absorbs the financial hit that will follow U.S. drug pricing reform: safety-net hospitals or powerful manufacturers. And in that fight, the governments effort at rebates looks less like modernization than an outright risk shift.

The AHA (but on behalf of the safety-net hospitals) vs. HRSA, in front of the pharmaceutical industry’s rebate architecture by ideal design. Replaced upfront discounts with the use of post-sale rebates. By late 2025, tensions erupted into conflict which continued essentially unabated into 2026. Where? In federal court (the U.S. District Court for Maine, and the First Circuit). As the 340B program was intended to support care for poor, rural and medically underserved patients. At first, hospitals would pay the entire price upfront and then throw themselves on the mercy of a data-heavy claims process for reimbursement after the fact. That is the basic scandal: It pressures hospitals to act as if they were free lenders of cash to drug manufacturers.

The administration also argues that rebates deter abuse, limit overlap with Inflation Reduction Act pricing and accountability. However, brutal facts cannot be hidden behind policy slogans. Outfits with comfortable cash cushions or health systems with recurring debt make for difficult bedfellows, but most hospitals tend to operate in such a manner. They are operating emergency departments, behavioral health services (treating addiction), opioid treatment programs and community clinics all on razor-thin margins. The purpose of a rebate system is to push payment back so far as to be lethal for liquidity even if the nominal discount will ever materialise. Now in public finance timing is everything. Access can die between the delay and the pass.

The AHA’s challenge is strong, legally, because it focuses on the fundamental Administrative Procedure Act problem with the way this got rolled out. Such a radical change with huge budgetary implications cannot be pushed through because of an administration’s impatience. Agencies only explain themselves, balance reliance interests, and face evidence that their own policy may cause injury. The government cannot blithely discard the idea that switch costs are important, if it has built decades of operations on up front discounts among hospitals. That is not reform. That is bureaucratic amnesia.

The deeper issue is institutional. The rebate model has a perverse logic that means public hospitals, rural systems and safety-net providers arguably the weakest actors in health care are expected to bear the burden of policymakers’ experiments aimed at restraining stronger actors. That is upside-down governance. If Washington wishes to avoid gaming, it should go after gaming. If it wants price transparency, then, it ought to create a mechanism that does not require hospitals to write big checks and wait for pharmaceutical gatekeepers to approve repayment.

Ensure Initials Discounts for safety net providers

An upfront discount is actually not a procedural detail: it is the lifeblood that allows safety-net hospitals to purchase drugs now, and treat patients now. Switching them out for rebates requires hospitals to pay upfront, deal with the delay and take on the risk. That is particularly perilous to institutions that are already running on a knife edge of failure. In practice, the model instead makes lenders of hospitals (willing or otherwise), to drug companies.

And tie hospital cash flow mechanics to put in place and separate anti abuse enforcement from.

Policymakers should look to ensure that it no longer happens by going straight for the abuse through audits, verification and penalties. But they should not upend the entire payment system and penalize all safety-net providers for the misdeeds of a few. Enforcement belongs in compliance, not in the hospital operating budget.

Establish a fast dry dispute process for rebate claims

A rebate scheme absent of a swift dispute resolution mechanism is a bureaucratic dead-end. The money associated wtih life-saving medicines cannot take months as hospitals continue to pay vendors, staff and service provider costs. The system should have clear deadlines and evidence rules, provisional payment protection while claims are being assessed. Otherwise, it is a bauble of administrative order that is the same as nothing other than a shock to cash flow.

Exclude hospitals facing high burden obligations from any pilot model

The first places we should start testing this are low income and safety-net facilities, such as rural hospitals or trauma centers. They are both the least able to absorb uncertainty and the most likely to suffer immediate losses. Testing risk on fragile hospitals is not cautious innovation; it is policy experimentation on the most vulnerable institutions.

Deny any further national rollout without full impact analysis

No national expansion will occur until regulators can ensure that the model does not adversely impact liquidity, access, staffing or patient care. This analysis should be its own independent, data-driven and public document. This drives the government by theory, not evidence which does not keep emergency departments open in practice.

In one sentence: Defense of the safety net should be first, and an anti-police abuse program second initially not vice versa.

The moral is clear: a health policy improving the accounting but undermining care, are not smart reforms. A glacial hand-off of risk from pharmaceuticals to the institutions that make up the safety net. When the safety net is obligated to pay for a system that exists only in relation to it, it is not a technical failure of morals but an intersection. It is structural.

Fransiscus Nanga Roka

Faculty of Law University 17 August 1945 Surabaya and Managing Partner Law Firm Victorious Indonesia